血浆N端B型利钠肽评估Ⅳ期肺癌患者心功能状况的价值

The value of plasma N-ternminal pro-brain natriuretic peptide levels in diagnosis of heart failure in lung cancer patients with stage ⅣThe value of plasma N-ternminal pro-brain natriuretic peptide levels in diagnosis of heart failure in lung cancer patients with stage Ⅳ

目的探讨应用血浆N端B型利钠肽（NT-proBNP）评定Ⅳ期肺癌患者心功能状况的价值。方法将87例Ⅳ期肺癌患者根据有无呼吸困难表现分为呼吸困难组及非呼吸困难组，呼吸困难组根据临床表现、心电图、超声心动图分为心力衰竭性呼吸困难及非心力衰竭性呼吸困难组。应用免疫荧光法测定87例Ⅳ期肺癌患者血浆NT—proBNP值，分别比较两组的差别。结果87例患者中存在不同程度呼吸困难58例，占66．7％，其NT—proBNP均值为（2486．87±327．72）ng／L，无呼吸困难29例，占33．3％，其NT—proBNP均值为（586．84±129．63）ng／L，两组NT—proBNP均值比较差异有统计学意义（P〈0．05）。呼吸困难组中心力衰竭性呼吸困难34例，占58．6％，其NT—proBNP均值为（3476．68±644．72）ng／L，非心力衰竭性呼吸困难24例，占41．4％，其NT—proBNP均值为（1836．68±439．48）ng／L，两组NT-proBNP均值比较差异有统计学意义（P〈0．05）。心力衰竭性呼吸困难占总患者数的39．1％（34／87）。结论血浆NT-proBNP检测有助于Ⅳ期肺癌合并心力衰竭的诊断。

Objective To investigate the clinical value of the plasma N-terminal pro-brain natriuretic peptide levels in lung cancer patients with stage Ⅳ. Methods 87 lung cancer patients with stage Ⅳ were divided into two groups： dyspnea group （58 cases） and non-dyspnea group （29 cases）. In dyspnea group, according to Heart failure, the cases were divided into two groups： heart failure dyspnea group （34 cases） and non-heart fail- ure dyspnea group （24 cases）. The plasma NT-proBNP level was measured by mmunofluorescence method. The data was analyzed by SPSS 13.0. Results The plasma NT-proBNP level of the cases with dyspnea group and non- dyspnea group was（2486.87±327.72）ng/L and （586.84±129.63）ng/L, respectively. There was a significant differ- ence between dyspnea cases and non-dyspnea cases （P〈0.05）. In heart failure dyspnea group and non-heart fail- ure dyspnea group, the plasma NT-proBNP level was （3476.68±644.72）ng/L and （1836.68±439.48）ng/L, respectively. The significant difference was also observed （P〈0.05）. Conclusion The plasma level of NT-proBNP is helpful to diagnose heart failure in lung cancer patients with stage Ⅳ.